EnerSpar Corp. (TSE:NRX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NurExone Biologic Inc. reports progress on regulatory fronts and corporate growth, including preclinical advances for its ExoPTEN drug and expansion of its financial footprint with an uplisting to the OTCQB Venture Market. The biopharmaceutical company also highlights a net loss increase in Q2 2024 compared to the same quarter in the previous year but reveals an improved cash position and working capital.
For further insights into TSE:NRX stock, check out TipRanks’ Stock Analysis page.